GenEpoch - genetic startap to treat obesity

GenEpoch

Changing future by shaping people

Our mission

At GENEPOCH, we are redefining the future of obesity treatment by targeting its genetic roots. Our mission is to develop safe, effective, and lasting therapies using CRISPR gene-editing and artificial intelligence — helping people gain control over their health by enhancing metabolism and increasing muscle composition.
We believe that science should serve humanity. That’s why we’re building the world’s first precision obesity therapy designed not to manage symptoms, but to resolve the cause — at the molecular level.

"Genes load the gun, but environment pulls the trigger."
— Dr. George Bray, leading obesity researcher and founder of the Pennington Biomedical Research Center

From Gene to Transformation
GENEPOCH's technology starts where conventional treatments stop — in your DNA. We identify specific gene sequences responsible for fat storage and low muscle mass, and reprogram them using CRISPR-based precision tools. Our AI models analyze entire DNA chains to personalize treatment and ensure long-term success.
This is not a diet. It’s not a drug. It’s a biological transformation — from the inside out.

GENEPOCH itself was founded in Zurich in 2023 with a single mission — to change the way the world treats obesity.
It all started when our founder, Angelina Belareva, brought together a global team of scientists, engineers, and visionaries to tackle one of the most pressing health challenges of our time — by addressing it at the genetic level.
From early lab work and in silico modeling to AI-powered gene targeting and experimental trials, our journey has been driven by science, ethics, and a belief in human potential.
Today, we are building breakthrough therapies that aim not just to reduce weight — but to reprogram the biology behind it. This is not a treatment. It’s a transformation.

Timeline of our project

Experiments in silico (Done)

We completed computational simulations and gene-sequence modeling using neural networks and CRISPR planning tools. This phase validated the target genes responsible for obesity and muscle composition, including MSTN, ACTN3, FTO, MC4R, and TMEM18.

Experiments with circular DNA of E.coli (In Progress)

We are currently assembling and testing modified plasmids in E.coli to express obesity-related genes. These bacterial models help us evaluate gene functionality before proceeding to more complex organisms.

Experiments with linear DNA in model organisms

Next, we will test edited genes in organisms with linear DNA structures, such as lab mice. This step is crucial for understanding gene expression in eukaryotic systems and for transitioning from bacterial to mammalian models.

Experiments with human fat cells

This phase focuses on in vitro testing of gene edits in cultured human adipose cells. We aim to observe how genetic modifications influence fat storage, muscle development, and metabolic markers at the cellular level.

Making adjustments to GenEpoch-AI 0.3 algorithms

Based on biological feedback from prior phases, we will retrain and refine our AI algorithms. The goal is to optimize gene target prediction and CRISPR editing precision across diverse genomic profiles.

Approval and initiation of therapy in humans

Upon successful preclinical validation, we will begin legal procedures for clinical trials, followed by first-in-human testing. This will mark the transition of GENEPOCH from lab to life-changing therapy.

Start sponsoring us right now

Meet Our Leaders

The smartest people work every day to provide the best future

Angelina Belareva

CEO & Founder

The visionary behind GENEPOCH and the driving force of the company. With a background in finance and a strong track record in startup growth, Angelina brings strategic leadership and marketing expertise that have transformed GENEPOCH from concept to a global biotech initiative.
Andreas Swirin

Technical Director § Co-Founder

As co-founder and technical lead, Andreas combines academic experience in digital technologies with a multidisciplinary scientific background. He oversees research and development, ensuring the scientific integrity and innovation of GENEPOCH’s core solutions.
Daniel Ovakimian

Executive Director

A seasoned executive with extensive leadership experience, Daniel is both a legal expert and a specialist in neural network development. He guides the company’s strategic direction, legal framework, and AI-driven advancements in genetic research.

Some Statistics

Obesity isn’t a lifestyle problem — it’s a global health crisis.

70 %

U.S. adults are overweight or obese

And that just only official statistics!
90 %

Of diets fail within the first year

Most weight-loss attempts end in regain.
45 %

Of adults globally want to lose weight

But few have access to effective tools.
25 %

Оf children aged 5–17 are overweight or obese

An alarming rise in early-life risk factors.
80 %

Оf obesity is genetically influenced

Which is why precision gene therapy matters.
5 %

Of global research funding goes to obesity

Despite its role in heart disease, diabetes, and cancer.

Start sponsoring us with only 1 dollar

How can you help us in our mission?

We are an independent initiative with no funding from universities, corporations, or public institutions.
Everything we build is rooted in one belief: that cutting-edge science can empower millions to reclaim their health and future. To sustain and scale our work, we rely on mission-aligned individuals — not institutions.
If you share our urgency and vision, your support can directly accelerate the development of life-changing technologies.
Join us at the earliest stage.
Your contribution isn’t just funding — it’s impact.

Scientific Excellence

Our team combines expertise in genetics, artificial intelligence, and biomedical innovation. Every step we take is grounded in scientific rigor and a deep commitment to quality. We don’t follow trends — we create breakthroughs that matter and change tomorrow.

Why will we succeed?

GENEPOCH is built on validated science and a clear market need. Our strategy has been backed by academic research and early investor interest. With a first-mover advantage in gene-based obesity treatment, we’re positioned to lead a health revolution.

Human-Centered Innovation

We develop technology not just for systems — but for real people with a real problem of overweighting. From our algorithms to our long-term vision, we focus on what truly improves lives. Every solution we create is tailored to real-world needs and individual health outcomes.

Based on our project, a full undergraduate thesis in marketing by Kate Ryabova was developed, providing a comprehensive analysis and validation of our concept. The research demonstrates the strong market potential and strategic viability of GENEPOCH.

Here you can review a part of it, with the author’s permission.